Brought to you by 
Bioenvision and Ilex to co-develop clofarabine
18 Apr 2005
Executive Summary
Bioenvison and Ilex Oncology will develop Bioenvision's clofarabine, a nucleoside analog in Phase II clinical trials to treat malignancies such as lymphoma and leukemia, and in Phase I trials for solid tumors. Bioenvision paid Ilex $1.35mm in cash up front.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bioenvision and Ilex to co-develop clofarabine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice